期刊文献+

Inflammation-based factors and prognosis in patients with colorectal cancer 被引量:13

Inflammation-based factors and prognosis in patients with colorectal cancer
下载PDF
导出
摘要 Several parameters for predicting survival in patients with colorectal cancer have been identified, including the performance status, age, gender and tumor-nodemetastasis(TNM) stage. Although the TNM stage is important and useful for predicting the prognosis and determining the appropriate treatment, it is well known that the survival time varies widely, even in patients with the same stage of disease. Therefore, the identification of new parameters capable of more precisely predicting patient survival is needed to help select the optimal treatment, especially in patients in the advanced stage of disease. Although the TNM stage reflects the tumor characteristics, cancer progression and survival are not determined solely based on the local characteristics of the tumor, but also the host systemic immune/inflammatory response. Therefore, using a combination of parameters that reflect both tumor characteristics and the host systemic inflammatory status is thought to be important for accurately predicting patient survival. Several parameters for predicting survival in patientswith colorectal cancer have been identified, includingthe performance status, age, gender and tumor-nodemetastasis(TNM) stage. Although the TNM stage isimportant and useful for predicting the prognosis anddetermining the appropriate treatment, it is well knownthat the survival time varies widely, even in patients withthe same stage of disease. Therefore, the identificationof new parameters capable of more precisely predictingpatient survival is needed to help select the optimaltreatment, especially in patients in the advanced stageof disease. Although the TNM stage reflects the tumorcharacteristics, cancer progression and survival are notdetermined solely based on the local characteristics ofthe tumor, but also the host systemic immune/inflammatoryresponse. Therefore, using a combination ofparameters that reflect both tumor characteristics andthe host systemic inflammatory status is thought to beimportant for accurately predicting patient survival.
出处 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2015年第8期111-117,共7页 世界胃肠肿瘤学杂志(英文版)(电子版)
关键词 Colorectal cancer Platelet-to-lymphocyteratio PROGNOSIS GLASGOW PROGNOSTIC Score C-reactiveprotein Neutrophil-to-lymphocyte ratio Inflammationbasedfactor NUTRITIONAL PROGNOSTIC Index Colorectal cancer Platelet-to-lymphocyte ratio Prognosis Glasgow Prognostic Score C-reactive protein Neutrophil-to-lymphocyte ratio Inflammation-based factor Nutritional Prognostic Index
  • 相关文献

参考文献56

  • 1Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, RosenbergHM, Vernon SW, Cronin K, Edwards BK. The annual reportto the nation on the status of cancer, 1973-1997, with a specialsection on colorectal cancer. Cancer 2000; 88: 2398-2424 [PMID:10820364 DOI: 10.1002/(SICI)1097-0142(20000515)88:10<2398::AIDCNCR26>3.0.CO;2-I].
  • 2Simmonds PC. Palliative chemotherapy for advanced colorectalcancer: systematic review and meta-analysis. Colorectal CancerCollaborative Group. BMJ 2000; 321: 531-535 [PMID: 10968812DOI: 10.1136/bmj.321.7260.531].
  • 3Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survivalof patients with advanced colorectal cancer improves with theavailability of fluorouracil-leucovorin, irinotecan, and oxaliplatin inthe course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID:15051767 DOI: 10.1200/JCO.2004.11.037].
  • 4Saltz LB, Clarke S, Dz-Rubio E, Scheithauer W, Figer A, WongR, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, SirzF, Cassidy J. Bevacizumab in combination with oxaliplatin-basedchemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019[PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930].
  • 5Van Cutsem E, Kne CH, Hitre E, Zaluski J, Chang Chien CR,Makhson A, D'aens G, Pint T, Lim R, Bodoky G, Roh JK,Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J,Rougier P. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417[PMID: 19339720 DOI: 10.1056/NEJMoa0805019].
  • 6Chibaudel B, Tournigand C, Andr-T, de Gramont A. Therapeuticstrategy in unresectable metastatic colorectal cancer. Ther Adv MedOncol 2012; 4: 75-89 [PMID: 22423266 DOI: 10.1177/1758834011431592].
  • 7Sobin L, Gospodarowicz M, Wittekind C. International againstCancer. TNM classification of malignant tumors, 7th ed. New York:Wiley-Blackwell, 2009: 73-77.
  • 8Kang SM, Maeda K, Onoda N, Chung YS, Nakata B, NishiguchiY, Sowa M. Combined analysis of p53 and vascular endothelialgrowth factor expression in colorectal carcinoma for determinationof tumor vascularity and liver metastasis. Int J Cancer 1997; 74:502-507 [PMID: 9355971 DOI: 10.1002/(SICI)1097-0215(19971021)74:5<502::AID-IJC4>3.0.CO;2-7].
  • 9Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, YamashitaY, Onoda N, Kato Y, Nitta A, Arimoto Y. Tumor angiogenesis as apredictor of recurrence in gastric carcinoma. J Clin Oncol 1995; 13:477-481 [PMID: 7531224].
  • 10Giatromanolaki A, Sivridis E, Koukourakis MI. Angiogenesis incolorectal cancer: prognostic and therapeutic implications. Am JClin Oncol 2006; 29: 408-417 [PMID: 16891872 DOI: 10.1097/01.coc.0000221317.56731.4e].

同被引文献51

引证文献13

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部